News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
NanoBio Corporation and GlaxoSmithKline Commence Phase 3 Studies of Nanoemulsion-based OTC Treatment for Cold Sores
May 11, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NanoBio® Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare (GSK CH).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
GlaxoSmithKline
MORE ON THIS TOPIC
Immunology and inflammation
Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered
September 19, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
September 18, 2025
·
2 min read
·
Tristan Manalac
Pain
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis
September 18, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Deep Dive: Oral Obesity Drugs on the Cusp
September 18, 2025
·
3 min read
·
Heather McKenzie
